Related Experiment Video

Updated: May 11, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Bleeding risk in atrial fibrillation patients taking vitamin K antagonists: systematic review and meta-analysis

L C Lopes1, F A Spencer, I Neumann

  • 1Pharmaceutical Sciences Postgraduate Course, University of Sorocaba, UNISO, Sorocaba, Brazil. luslopes@terra.com.br

Clinical Pharmacology and Therapeutics
|May 15, 2013
PubMed

Insights

Vitamin K antagonists (VKAs) help prevent stroke in atrial fibrillation (AF) patients but carry a bleeding risk. This review found major bleeding occurs at an estimated rate of 2.51 per 100 patient-years in AF patients using VKAs.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Research

Background:

  • Atrial fibrillation (AF) increases stroke risk, necessitating anticoagulant therapy.
  • Vitamin K antagonists (VKAs) are commonly prescribed for stroke prevention in AF.
  • VKA therapy is associated with an increased risk of bleeding complications.

Purpose of the Study:

  • To determine the pooled rate of major bleeding events in patients with atrial fibrillation (AF) treated with Vitamin K antagonists (VKAs).
  • To provide an evidence-based estimate of bleeding risk for patients considering VKA therapy.

Main Methods:

  • Systematic review of eligible studies.
  • Inclusion of over 342,699 patients across 51 studies.
  • Pooled analysis to estimate the rate of major bleeding.

Main Results:

  • The pooled estimate for major bleeding rate was 2.51 per 100 patient-years.
  • A 99% confidence interval for the bleeding rate was calculated (2.03-3.11).
  • This rate represents a key risk metric for VKA therapy in AF.

Conclusions:

  • Major bleeding is a significant risk associated with VKA use in AF patients.
  • The findings offer crucial data for risk-benefit assessments in clinical practice.
  • Patients and clinicians can use these estimates to inform treatment decisions regarding anticoagulation.

More Related Videos

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...